Disclosed herein is the use of an angiotensin II receptor 1 (AT-1) antagonist for the manufacture of a pharmaceutical composition comprising a therapeutically effective amount of said AT-1 antagonist for the treatment of a systemic disease in cats, wherein the systemic disease is selected from the group of cardiovascular diseases, vascular diseases, and metabolic disorders, wherein said angiotensin II receptor (AT-1) antagonist is a sartan selected from the group consisting of: candesartan, eprosartan, irbesartan, losartan, tasosartan, telmisartan, valsartan, and a pharmaceutically acceptable salt thereof.
